Bora Pharmaceuticals (6472) Aandelenoverzicht
Bora Pharmaceuticals Co., LTD. onderzoekt en ontwikkelt, produceert, distribueert en verkoopt farmaceutische producten wereldwijd. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 5/6 |
| Prestaties in het verleden | 2/6 |
| Financiële gezondheid | 4/6 |
| Dividenden | 4/6 |
6472 Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Bora Pharmaceuticals Co., Ltd. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | NT$426.00 |
| 52 Week Hoogtepunt | NT$795.00 |
| 52 Week Laag | NT$330.50 |
| Bèta | 0.43 |
| 1 maand verandering | 9.23% |
| 3 maanden verandering | 3.52% |
| 1 Jaar Verandering | -39.44% |
| 3 jaar verandering | -12.65% |
| 5 jaar verandering | 242.35% |
| Verandering sinds IPO | 1,036.51% |
Recent nieuws en updates
Narratiefupdate • Jun 25
6472: Higher Future P/E Assumptions Will Support Long Term Earnings Power
The analyst price target for Bora Pharmaceuticals has changed slightly from NT$698.22 to NT$700.86. Analysts attribute this revision to updated assumptions for revenue growth, profit margins and future P/E, which are viewed as key drivers of the new valuation.Narratiefupdate • Jun 05
6472: Revised Earnings And Margin Outlook Will Support Long Term Earnings Power
Analysts have reset their fair value estimate for Bora Pharmaceuticals from NT$741.35 to NT$698.22, reflecting updated views on revenue growth, profit margins and future P/E assumptions. What's in the News No recent news items, periodical coverage, or key developments were provided for Bora Pharmaceuticals, so there are no current events to highlight for now.Narratiefupdate • Apr 28
6472: Renewed GSK Manufacturing Agreement Will Support Long Term Earnings Power
Analysts have raised their price target on Bora Pharmaceuticals by NT$741.35, reflecting slightly higher assumptions for revenue growth, profit margins and future P/E multiples. What's in the News Bora Pharmaceuticals and GSK renewed a five year manufacturing agreement, extending GSK's access to multiple Bora sites, including the Mississauga facility acquired from GSK in 2020 and the oral solid dose site in Maple Grove, Minnesota (Key Developments).Recent updates
Narratiefupdate • Jun 25
6472: Higher Future P/E Assumptions Will Support Long Term Earnings Power
The analyst price target for Bora Pharmaceuticals has changed slightly from NT$698.22 to NT$700.86. Analysts attribute this revision to updated assumptions for revenue growth, profit margins and future P/E, which are viewed as key drivers of the new valuation.Narratiefupdate • Jun 05
6472: Revised Earnings And Margin Outlook Will Support Long Term Earnings Power
Analysts have reset their fair value estimate for Bora Pharmaceuticals from NT$741.35 to NT$698.22, reflecting updated views on revenue growth, profit margins and future P/E assumptions. What's in the News No recent news items, periodical coverage, or key developments were provided for Bora Pharmaceuticals, so there are no current events to highlight for now.Narratiefupdate • Apr 28
6472: Renewed GSK Manufacturing Agreement Will Support Long Term Earnings Power
Analysts have raised their price target on Bora Pharmaceuticals by NT$741.35, reflecting slightly higher assumptions for revenue growth, profit margins and future P/E multiples. What's in the News Bora Pharmaceuticals and GSK renewed a five year manufacturing agreement, extending GSK's access to multiple Bora sites, including the Mississauga facility acquired from GSK in 2020 and the oral solid dose site in Maple Grove, Minnesota (Key Developments).Narratiefupdate • Apr 12
6472: Renewed GSK Manufacturing Partnership Will Support Long Term Earnings Power
Analysts have adjusted their price target on Bora Pharmaceuticals to reflect updated assumptions around revenue growth of 29.12% and a profit margin of 20.96%. The implied fair value remains around NT$741.35 based on a forward P/E of 13.69.Narratiefupdate • Mar 28
6472: Renewed GSK Manufacturing Agreement Will Support Long Term Earnings Power
Analysts have inched up their price target on Bora Pharmaceuticals to NT$741.35 from NT$741.02, citing updated assumptions that combine a higher revenue growth outlook of 29.58% with a slightly stronger profit margin of 20.74% and a modestly lower future P/E of 13.69. What's in the News Bora Pharmaceuticals has scheduled a board meeting on March 11, 2026, to review the 2025 fourth quarter consolidated financial statement (Key Developments).Narratiefupdate • Mar 13
6472: Renewed GSK Manufacturing Alliance Will Drive Long Term Upside Potential
Analysts have kept their NT$741.02 price target for Bora Pharmaceuticals unchanged, pointing to stable views on fair value, discount rate, revenue growth assumptions, profit margins, and future P/E as the key reasons for maintaining their stance. What's in the News Bora Pharmaceuticals and GSK renewed a five year manufacturing partnership, extending their existing relationship and broadening GSK access to multiple Bora sites, including the oral solid dose facility in Maple Grove, Minnesota (Key Developments).Narratiefupdate • Feb 26
6472: Renewed GSK Partnership And Corealis Alliance Will Support Future Upside
Analysts have kept their NT$741.02 price target for Bora Pharmaceuticals unchanged, citing largely stable assumptions on the discount rate, revenue growth, profit margin, and a slightly lower future P/E multiple. What's in the News Bora Pharmaceuticals and GSK renewed a five year manufacturing partnership, which gives GSK access to multiple Bora sites, including the Mississauga facility acquired from GSK in 2020 and a newer oral solid dose site in Maple Grove, Minnesota (Key Developments).Narratiefupdate • Feb 11
6472: Corealis Alliance Will Support Future Upside Through End To End Development
Analysts have modestly adjusted their price target on Bora Pharmaceuticals to reflect updated assumptions around discount rate, revenue growth, profit margin and future P/E. This has resulted in a refreshed fair value estimate of about NT$741.02 per share.Narratiefupdate • Jan 28
6472: Corealis Alliance Will Drive Future Upside Through Integrated Development Path
Analysts have trimmed their price target for Bora Pharmaceuticals to reflect a fair value update to $741.02 from $788.87, citing slightly adjusted revenue growth assumptions, a modestly higher profit margin outlook, and a lower future P/E input in their models. What's in the News Bora Pharmaceuticals Co., Ltd.Narratiefupdate • Jan 11
6472: Corealis Alliance Will Support Future Upside Through Streamlined Development
Analysts have kept their price target for Bora Pharmaceuticals broadly unchanged at about $789, reflecting consistent assumptions on discount rate, revenue growth, profit margin and future P/E, and indicating that recent research has not materially shifted their valuation view. What's in the News Bora Pharmaceuticals Co., Ltd.Narratiefupdate • Dec 20
6472: Alliance With Corealis Will Support Stronger Long Term Performance
Analysts have modestly reiterated their outlook on Bora Pharmaceuticals, keeping the fair value estimate steady at $788.87 per share, as they see no material changes to projected revenue growth, margins, or valuation multiples. What's in the News Bora Pharmaceuticals and Corealis Pharma formed a strategic alliance to deliver integrated end to end oral solid dose development and manufacturing services, giving clients a single pathway from early formulation through commercial production (company announcement) The partnership combines Bora's global commercial infrastructure with Corealis' formulation and clinical scale manufacturing expertise, aiming to accelerate timelines and reduce complexity for biotech and pharma innovators (company announcement) Bora and Corealis will align project management and quality systems across the drug development lifecycle to lower outsourcing risk and improve reliability from discovery through commercial launch (company announcement) Valuation Changes Fair Value Estimate is unchanged at NT$788.87 per share, indicating no revision to Bora Pharmaceuticals' intrinsic value assessment.Narratiefupdate • Dec 06
6472: Improved Profit Margins Will Support Stronger Long Term Performance
Narrative Update Analysts have nudged their price target on Bora Pharmaceuticals slightly higher to approximately $789 per share, reflecting modestly improved long term profit margin expectations, even though projected revenue growth has been tempered slightly. Valuation Changes Fair Value Estimate: unchanged at approximately NT$788.87 per share, indicating no material revision to the intrinsic value assessment.Narratiefupdate • Nov 21
6472: Improved Profit Margins Will Drive Stronger Performance Ahead
Analysts have lowered their price target for Bora Pharmaceuticals from $872.67 to $788.87. This adjustment is due to reduced revenue growth expectations, which are partially offset by projections of improved profit margins and a lower forward price-to-earnings ratio.Narratiefupdate • Sep 28
US CDMO Expansion And Specialty Focus Will Strengthen Position
The consensus analyst price target for Bora Pharmaceuticals has been revised upward, primarily driven by a significant increase in the company's expected future P/E multiple, with the fair value rising from NT$847.46 to NT$872.67. What's in the News Bora Pharmaceuticals is making significant investments to expand manufacturing and packaging capabilities at its Maple Grove, Minnesota facility, acquired via the $210 million Upsher-Smith Laboratories deal in 2024.Nieuw narratief • Jul 20
US Facility Modernization Will Secure Future Specialty Success
Strategic shift to high-value CDMO services and facility upgrades has improved margins, driven growth, and positioned the company for market share gains.Analyseartikel • Mar 30
Cautious Investors Not Rewarding Bora Pharmaceuticals Co., LTD.'s (TWSE:6472) Performance Completely
With a median price-to-earnings (or "P/E") ratio of close to 20x in Taiwan, you could be forgiven for feeling...Analyseartikel • Jan 20
We Think Bora Pharmaceuticals (TWSE:6472) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Nov 21
Bora Pharmaceuticals' (TWSE:6472) Earnings Are Weaker Than They Seem
Bora Pharmaceuticals Co., LTD.'s ( TWSE:6472 ) robust earnings report didn't manage to move the market for its stock...Analyseartikel • Oct 04
Does Bora Pharmaceuticals (TWSE:6472) Deserve A Spot On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analyseartikel • Jul 18
Investors Appear Satisfied With Bora Pharmaceuticals Co., LTD.'s (TWSE:6472) Prospects
Bora Pharmaceuticals Co., LTD.'s ( TWSE:6472 ) price-to-earnings (or "P/E") ratio of 34.2x might make it look like a...Analyseartikel • Jun 13
Is Bora Pharmaceuticals Co., LTD. (TWSE:6472) Trading At A 44% Discount?
Key Insights The projected fair value for Bora Pharmaceuticals is NT$1,369 based on 2 Stage Free Cash Flow to Equity...Analyseartikel • Apr 10
Bora Pharmaceuticals Co., LTD. (TWSE:6472) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected
Bora Pharmaceuticals Co., LTD. ( TWSE:6472 ) shareholders have had their patience rewarded with a 33% share price jump...Analyseartikel • Apr 08
Bora Pharmaceuticals (TWSE:6472) Could Easily Take On More Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Mar 14
Shareholders Can Be Confident That Bora Pharmaceuticals' (TWSE:6472) Earnings Are High Quality
Even though Bora Pharmaceuticals Co., LTD. ( TWSE:6472 ) posted strong earnings, investors appeared to be underwhelmed...Rendement voor aandeelhouders
| 6472 | TW Pharmaceuticals | TW Markt | |
|---|---|---|---|
| 7D | -1.4% | 4.0% | -2.7% |
| 1Y | -39.4% | -3.9% | 101.2% |
Rendement versus industrie: 6472 presteerde slechter dan de TW Pharmaceuticals -sector, die het afgelopen jaar een rendement van -3.9 % opleverde.
Rendement versus markt: 6472 presteerde slechter dan TW Market, dat het afgelopen jaar een rendement van 101.2 % opleverde.
Prijsvolatiliteit
| 6472 volatility | |
|---|---|
| 6472 Average Weekly Movement | 6.8% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in TW Market | 12.1% |
| 10% least volatile stocks in TW Market | 2.6% |
Stabiele aandelenkoers: 6472 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de TW markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van 6472 is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2007 | n/a | Bobby Sheng | www.bora-corp.com |
Bora Pharmaceuticals Co., LTD. onderzoekt en ontwikkelt, produceert, distribueert en verkoopt farmaceutische producten wereldwijd. Het bedrijf opereert via de segmenten Sales, Contract Development & Manufacturing Organization en Other.
Bora Pharmaceuticals Co., Ltd. Samenvatting
| 6472 fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | NT$53.75b |
| Inkomsten(TTM) | NT$1.68b |
| Inkomsten(TTM) | NT$18.54b |
32.2x
Koers/Winstverhouding2.9x
P/S-verhoudingIs 6472 overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| 6472 resultatenrekening (TTM) | |
|---|---|
| Inkomsten | NT$18.54b |
| Kosten van inkomsten | NT$11.13b |
| Brutowinst | NT$7.41b |
| Overige uitgaven | NT$5.72b |
| Inkomsten | NT$1.68b |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 13.21 |
| Brutomarge | 39.96% |
| Nettowinstmarge | 9.08% |
| Schuld/Eigen Vermogen Verhouding | 100.9% |
Hoe presteerde 6472 op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
2.3%
Huidig dividendrendement75%
UitbetalingsratioBetaalt 6472 een betrouwbaar dividend?
Zie 6472 dividendgeschiedenis en benchmarks| Bora Pharmaceuticals dividenddata | |
|---|---|
| Ex Dividend Datum | Jul 31 2026 |
| Betaaldatum dividend | Aug 26 2026 |
| Dagen tot Ex-dividend | 21 days |
| Dagen tot dividendbetaaldatum | 47 days |
Betaalt 6472 een betrouwbaar dividend?
Zie 6472 dividendgeschiedenis en benchmarksBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/09 12:32 |
| Aandelenkoers aan het einde van de dag | 2026/07/09 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Bora Pharmaceuticals Co., Ltd. wordt gevolgd door 8 analisten. 5 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Chenghsin Lin | J.P. Morgan |
| Yang Huang | J.P. Morgan |
| Hsuan Chen | KGI Securities Co. Ltd. |